Epigenetics market forecast tops $35B by 2030

The Business Research Company says the global epigenetics market will grow from $12.74 billion in 2025 to $15.62 billion in 2026, then reach $35.01 billion by 2030. The report points to precision medicine, cancer research and AI-driven genomic analysis as the main forces behind the expansion.

Why it matters: - The epigenetics market is moving from a research niche into a larger clinical and drug-development toolset. - Growth in precision medicine and cancer diagnostics is expanding demand for epigenetic assays, biomarkers and analysis platforms. - The market’s projected jump to $35.01 billion by 2030 signals major commercial opportunity across biotech, pharma and diagnostics.

What happened: - The Business Research Company released an epigenetics market report covering market size, trends and a global forecast for 2026-2035. - The report estimates the market will grow from $12.74 billion in 2025 to $15.62 billion in 2026. - The report projects the market will reach $35.01 billion by 2030. - The release was issued from London on Aug. 6, 2026.

The details: - The 2025-to-2026 increase implies a 22.6% compound annual growth rate. - The 2026-to-2030 forecast implies a 22.3% CAGR. - Historical growth has been driven by cancer research, academic genomics studies, sequencing technologies, molecular diagnostics and life sciences funding. - Future growth is expected to come from precision medicine, epigenetic therapeutics, personalized oncology, AI-powered genomic analysis and collaboration between pharmaceutical companies and research organizations. - The report highlights rising use of epigenetic biomarkers in cancer detection. - The report also points to growing demand for DNA methylation assays, high-throughput epigenetic analysis, epigenetics-focused drug discovery and bioinformatics platforms. - Epigenetics refers to changes in gene activity passed to daughter cells without changing the DNA sequence. - The release says epigenetic changes can contribute to cancers, reproductive health issues and cardiovascular diseases. - The release says epigenetics can help support earlier detection of some cancers. - The report says North America led the market in 2025 by size. - The Asia-Pacific region is forecast to post the fastest growth over the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company says the 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - The forecast suggests epigenetics is becoming more commercially relevant as medicine shifts toward targeted treatment and biomarker-driven decision-making. - The emphasis on AI, bioinformatics and methylation assays points to a market that is becoming more data-intensive and more integrated with diagnostics. - North America’s current lead and Asia-Pacific’s faster growth point to an established base in the U.S. and Canada, with demand widening in other regions.

What's next: - The market is expected to keep compounding through 2030 as precision oncology and epigenetic therapeutics broaden adoption. - Companies positioned in sequencing, biomarker detection, analytics and drug discovery may see continued demand as the field scales. - Regional growth in Asia-Pacific will likely remain a key watchpoint for suppliers and investors.

The bottom line: - Epigenetics is projected to more than double by 2030, driven by precision medicine and cancer-focused applications.